LAUSR

Capillaria boehmi affects the upper respiratory tract of domestic and wild canids. The aim of the present study was to investigate the efficacy of imidacloprid 10 % / moxidectin 2.5 % spot-on (Advocate®, Advantage® Multi, Bayer) in dogs naturally infected by C. boehmi. Twenty dogs infected with C. boehmi were randomly allocated to two groups: T1 (10 dogs) received a single treatment of Advocate® using the recommended dose on day 0 and T2 (10 dogs) served as an untreated control group. The reduction of the faecal egg counts (EPG) from baseline (days -6 ± 2 and -2 ± 2) to study completion was set as the primary efficacy criterion; clinical assessments of the upper respiratory tract and a rhinoscopy to visualize the parasites were used as secondary efficacy criteria. Eight dogs in T1 were not shedding eggs on days 28 ± 2 (reduction of EPG 99.66 %). A second treatment was administered to two dogs still positive on days 30 ± 3. A second efficacy evaluation was performed on days 42 ± 2 (study completion), when the two dogs tested negative. The mean number of EPG at study completion was 0 in T1 and 368.49 in T2. The difference between the groups was statistically significant (P < 0.01). Treatment efficacy at study completion was 100 %. None of the T1 dogs showing clinical signs on day 0 were symptomatic on days 28 ± 2. No adverse events occurred. The results show that Advocate® is safe and effective in the treatment of canine nasal capillariosis. Original Article WAAVP_2017.indb 65 29.06.17 15:33 S66 EndoparasitEs EndoparasitEs